Pharmaceutical

FLU-SV-mRNA by Curevac for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval

FLU-SV-mRNA is under clinical development by Curevac and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections.

Dec 20, 2023 - 18:00
FLU-SV-mRNA is under clinical development by Curevac and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections.
Read the original article

Tags:

Previous Article

NNC-05600004 by Novo Nordisk for Liver Diseases: Likelihood of Approval

Next Article

ND-10 ER by Theialife Sciences for Myopia: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages

STAT+: Pharmalittle: Novo faces patent challenge on Weg...

Oct 6, 2023

FDA AdCom to question efficacy and safety concerns with Eli Lilly’s Alzheimer’s drug

FDA AdCom to question efficacy and safety concerns with...

Jun 8, 2024

STAT+: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone

STAT+: Biden’s SOTU highlights pharma’s biggest politic...

Mar 8, 2024